For over 15 years, my research has focused on understanding the role of immune perturbations/inflammation and cancer risk. A molecular epidemiologist by training, I evaluate the role of both genetic and environmental influences on cancer risk, with a specific focus on pinpointing the specific immune mechanism involved in carcinogenesis. I have evaluated the role of immune perturbations from infections (e.g., hepatitis A, B, C; human papillomavirus), from autoimmune conditions, from behavioral characteristics (e.g., obesity) and from genetic variations among immune genes.
A large part of my research has focused on the etiology of hematopoietic malignancies, with ongoing work in understanding the role of the immune genes, such as human leukocyte antigens (HLA), and others particularly relevant genes for inflammation (e.g., tumor necrosis factor) in lymphoma etiology and survival. I have also devoted many years to understanding the immunological/genetic underpinnings related to infections and cancer, most notably in human papillomavirus and cervical cancer.
My currently funded research in lymphoma is derived from the Los Angeles County population, where we are evaluating the role of environmental and genetic risk factors for developing the incident lymphoma, for developing a recurrent lymphoma, and for surviving lymphoma. I also serve as a Steering Committee member to the California Teachers Study cohort where we evaluate the causes of multiple cancers. The unique linkages of this study with state-wide databases, including hospitalization, cancer registry, mortality databases, along with the detailed exposure information ascertained from the nearly 133,000 female participants enables our research team to evaluate life-long exposures (and changes) with regard to cancer risk, and in consideration of competing disease entities, including stroke and diabetes.
I am also an active researcher in large international consortia, including the International Lymphoma Epidemiology (InterLymph) Consortium where I served as its chair in 2013, the National Cancer Institute’s Cohort Consortium, and the National Institute of Health’s The Cancer Genome Atlas Cervix Working Group.